Given the elevated prevalence of PTH and migraine in female populations [68–70], and the documented sexual dimorphism in endocannabinoid signaling within the trigeminal system and pain associated brain regions [71, 72], future studies employing female TBI animal models are needed to evaluate the therapeutic potential of IMMA in both acute and persistent phases of PTH. Here, PTH is linked to migraine disorder.